{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:38:36Z","timestamp":1792348716816,"version":"4.4.0"},"reference-count":154,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHD"],"published-print":{"date-parts":[[2019,2,13]]},"DOI":"10.3233\/jhd-180320","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T11:44:25Z","timestamp":1547207065000},"page":"9-22","source":"Crossref","is-referenced-by-count":4,"title":["Disease-Modification in Huntington\u2019s Disease: Moving Away from a Single-Target Approach"],"prefix":"10.1177","volume":"8","author":[{"given":"Melanie P.","family":"Jensen","sequence":"first","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger A.","family":"Barker","sequence":"additional","affiliation":[{"name":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK"},{"name":"Cambridge Stem Cell Institute, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"2","key":"10.3233\/JHD-180320_ref1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in Huntington\u2019s disease: a very low clinical drug development success rate","volume":"6","author":"Travessa","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"10.3233\/JHD-180320_ref2","doi-asserted-by":"crossref","unstructured":"Canepa C , Burton B , Muhith A An elusive ciliopathy: Joubert syndrome. BMJ Case Rep. 2017;2017:bcr-2017-220459.","DOI":"10.1136\/bcr-2017-220459"},{"issue":"7707","key":"10.3233\/JHD-180320_ref3","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1038\/d41586-018-05176-z","article-title":"How the gene behind Huntington\u2019s disease could be neutralized","volume":"557","author":"Drew","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.3233\/JHD-180320_ref4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/jnnp-2014-308153","article-title":"Modelling the natural history of Huntington\u2019s disease progression","volume":"86","author":"Kuan","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.3233\/JHD-180320_ref5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nm.2313","article-title":"Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity","volume":"17","author":"Song","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"10.3233\/JHD-180320_ref6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.arcmed.2007.11.011","article-title":"Excitotoxic neuronal death and the pathogenesis of Huntington\u2019s disease","volume":"39","author":"Estrada Sanchez","year":"2008","journal-title":"Arch Med Res"},{"issue":"4","key":"10.3233\/JHD-180320_ref7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.2174\/1389450115666140115113734","article-title":"The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates?","volume":"15","author":"Gil-Mohapel","year":"2014","journal-title":"Curr Drug Targets"},{"issue":"3","key":"10.3233\/JHD-180320_ref8","first-page":"Cd006455","article-title":"Therapeutic interventions for disease progression in Huntington\u2019s disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.3233\/JHD-180320_ref9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1212\/WNL.0000000000003478","article-title":"A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease","volume":"88","author":"McGarry","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-180320_ref10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0000000000004209","article-title":"The CREST-E study of creatine for Huntington disease: A randomized controlled trial","volume":"89","author":"Hersch","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JHD-180320_ref11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamaneurol.382","volume":"70","author":"A randomized, double-blind, placebo-controlled study of latrepirdine in patients with mild to moderate Huntington disease","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.3233\/JHD-180320_ref12","doi-asserted-by":"crossref","unstructured":"A futility study of minocycline in Huntington\u2019s disease. Mov Disord. 2010;25(13):2219\u201324.","DOI":"10.1002\/mds.23236"},{"issue":"15","key":"10.3233\/JHD-180320_ref13","first-page":"1081","article-title":"A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter","volume":"335","author":"Hammer","year":"1996","journal-title":"AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med"},{"issue":"7685","key":"10.3233\/JHD-180320_ref14","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/d41586-017-08702-7","article-title":"The benefits of immunotherapy combinations","volume":"552","author":"Schmidt","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.3233\/JHD-180320_ref15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.celrep.2013.12.035","article-title":"PIK3CA, and PTEN aberrations in early-phase trials with PI3K\/AKT\/mTOR inhibitors: experience with 1,656 patients at MD Anderson Cancer Center","volume":"6","author":"Janku","year":"2014","journal-title":"Cell Rep"},{"issue":"5","key":"10.3233\/JHD-180320_ref16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson\u2019s and Huntington\u2019s diseases","volume":"109","author":"Yang","year":"2009","journal-title":"J Neurochem"},{"issue":"3","key":"10.3233\/JHD-180320_ref17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","article-title":"Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington\u2019s disease mice","volume":"1762","author":"Stack","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"10.3233\/JHD-180320_ref18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0306-4522(95)00527-7","article-title":"Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases","volume":"71","author":"Schulz","year":"1996","journal-title":"Neuroscience"},{"issue":"3","key":"10.3233\/JHD-180320_ref19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3940(01)02326-6","article-title":"Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington\u2019s disease transgenic mouse model","volume":"315","author":"Schilling","year":"2001","journal-title":"Neurosci Lett"},{"issue":"5","key":"10.3233\/JHD-180320_ref20","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","article-title":"Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington\u2019s disease","volume":"22","author":"Ferrante","year":"2002","journal-title":"J Neurosci"},{"issue":"10","key":"10.3233\/JHD-180320_ref21","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrn3570","article-title":"Choosing an animal model for the study of Huntington\u2019s disease","volume":"14","author":"Pouladi","year":"2013","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"10.3233\/JHD-180320_ref22","first-page":"397","volume":"57","author":"A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington\u2019s disease","year":"2001","journal-title":"Neurology"},{"issue":"10","key":"10.3233\/JHD-180320_ref23","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.3233\/JHD-180320_ref24","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00415-017-8647-0","article-title":"An open-label study to assess the feasibility and tolerability of rilmenidine for the treatment of Huntington\u2019s disease","volume":"264","author":"Underwood","year":"2017","journal-title":"J Neurol"},{"issue":"1","key":"10.3233\/JHD-180320_ref25","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/cdd.2008.110","article-title":"Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies","volume":"16","author":"Sarkar","year":"2009","journal-title":"Cell Death Differ"},{"issue":"6","key":"10.3233\/JHD-180320_ref26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/ng1362","article-title":"Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease","volume":"36","author":"Ravikumar","year":"2004","journal-title":"Nat Genet"},{"issue":"20","key":"10.3233\/JHD-180320_ref27","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1093\/hmg\/ddi331","article-title":"Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway","volume":"14","author":"Berger","year":"2005","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.3233\/JHD-180320_ref28","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nm985","article-title":"Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease","volume":"10","author":"Tanaka","year":"2004","journal-title":"Nat Med"},{"issue":"8","key":"10.3233\/JHD-180320_ref29","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.1074\/jbc.M609532200","article-title":"Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein","volume":"282","author":"Sarkar","year":"2007","journal-title":"J Biol Chem"},{"issue":"11","key":"10.3233\/JHD-180320_ref30","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/hmg\/ddq093","article-title":"Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington\u2019s disease","volume":"19","author":"Rose","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"5","key":"10.3233\/JHD-180320_ref31","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nchembio.79","article-title":"Novel targets for Huntington\u2019s disease in an mTOR-independent autophagy pathway","volume":"4","author":"Williams","year":"2008","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.3233\/JHD-180320_ref32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/hmg\/ddm294","article-title":"A rational mechanism for combination treatment of Huntington\u2019s disease using lithium and rapamycin","volume":"17","author":"Sarkar","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"7","key":"10.3233\/JHD-180320_ref33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1083\/jcb.200504035","article-title":"Lithium induces autophagy by inhibiting inositol monophosphatase","volume":"170","author":"Sarkar","year":"2005","journal-title":"J Cell Biol"},{"issue":"1-3","key":"10.3233\/JHD-180320_ref34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejphar.2010.08.035","article-title":"Activation of phosphatidylinositol 3-kinase\/Akt signaling pathway and endogenous nitric oxide are needed for the antiarrhythmic effect of centrally administered rilmenidine","volume":"647","author":"Yamanaka","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.3233\/JHD-180320_ref35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jnnp-2012-302441","article-title":"The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington\u2019s disease","volume":"84","author":"Barker","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9246","key":"10.3233\/JHD-180320_ref36","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(00)03310-9","article-title":"Motor and cognitive improvements in patients with Huntington\u2019s disease after neural transplantation","volume":"356","author":"Bachoud-Levi","year":"2000","journal-title":"Lancet"},{"issue":"4","key":"10.3233\/JHD-180320_ref37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1474-4422(06)70381-7","article-title":"Effect of fetal neural transplants in patients with Huntington\u2019s disease 6 years after surgery: a long-term follow-up study","volume":"5","author":"Bachoud-Levi","year":"2006","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.3233\/JHD-180320_ref38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ana.24174","article-title":"Mutant huntingtin is present in neuronal grafts in Huntington disease patients","volume":"76","author":"Cicchetti","year":"2014","journal-title":"Ann Neurol"},{"issue":"Pt 3","key":"10.3233\/JHD-180320_ref39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/brain\/awq328","article-title":"Neuronal degeneration in striatal transplants and Huntington\u2019s disease: potential mechanisms and clinical implications","volume":"134","author":"Cicchetti","year":"2011","journal-title":"Brain"},{"issue":"4","key":"10.3233\/JHD-180320_ref40","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s002210050877","article-title":"Behavioural recovery following striatal transplantation: effects of postoperative training and P-zone volume","volume":"128","author":"Brasted","year":"1999","journal-title":"Exp Brain Res"},{"issue":"2","key":"10.3233\/JHD-180320_ref41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1037\/0735-7044.114.2.431","article-title":"Behavioral recovery after transplantation into a rat model of Huntington\u2019s disease: dependence on anatomical connectivity and extensive postoperative training","volume":"114","author":"Brasted","year":"2000","journal-title":"Behav Neurosci"},{"issue":"2","key":"10.3233\/JHD-180320_ref42","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1460-9568.1992.tb00858.x","article-title":"Striatal graft-associated recovery of a lesion-induced performance deficit in the rat requires learning to use the transplant","volume":"4","author":"Mayer","year":"1992","journal-title":"Eur J Neurosci"},{"issue":"3","key":"10.3233\/JHD-180320_ref43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.neuroscience.2005.01.016","article-title":"Training specificity, graft development and graft-mediated functional recovery in a rodent model of Huntington\u2019s disease","volume":"132","author":"Dobrossy","year":"2005","journal-title":"Neuroscience"},{"key":"10.3233\/JHD-180320_ref44","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.pbr.2016.12.006","article-title":"Rehabilitation training in neural restitution","volume":"230","author":"Clinch","year":"2017","journal-title":"Prog Brain Res"},{"issue":"Pt 6","key":"10.3233\/JHD-180320_ref45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/brain\/awh145","article-title":"Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington\u2019s disease","volume":"127","author":"Peschanski","year":"2004","journal-title":"Brain"},{"key":"10.3233\/JHD-180320_ref46","doi-asserted-by":"crossref","first-page":"11758","DOI":"10.1038\/ncomms11758","article-title":"Human glia can both induce and rescue aspects of disease phenotype in Huntington disease","volume":"7","author":"Benraiss","year":"2016","journal-title":"Nat Commun"},{"issue":"5-6","key":"10.3233\/JHD-180320_ref47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pneurobio.2007.01.003","article-title":"Role of brain-derived neurotrophic factor in Huntington\u2019s disease","volume":"81","author":"Zuccato","year":"2007","journal-title":"Prog Neurobiol"},{"issue":"1","key":"10.3233\/JHD-180320_ref48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2014.05.032","article-title":"Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington\u2019s disease","volume":"83","author":"Plotkin","year":"2014","journal-title":"Neuron"},{"issue":"163","key":"10.3233\/JHD-180320_ref49","doi-asserted-by":"crossref","first-page":"163ra56","DOI":"10.1126\/scitranslmed.3004676","article-title":"alpha-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons","volume":"4","author":"Decressac","year":"2012","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.3233\/JHD-180320_ref50","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.neuron.2012.06.001","article-title":"\u201cHuntingtin holiday\u201d: progress toward an antisense therapy for Huntington\u2019s disease","volume":"74","author":"Lu","year":"2012","journal-title":"Neuron"},{"issue":"6","key":"10.3233\/JHD-180320_ref51","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/HJH.0b013e3281fc975a","article-title":"2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"25","author":"Mancia","year":"2007","journal-title":"J Hypertens"},{"key":"10.3233\/JHD-180320_ref52","first-page":"57","article-title":"The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction","author":"Remme","year":"2004","journal-title":"The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)"},{"issue":"3","key":"10.3233\/JHD-180320_ref53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/mds.870110317","article-title":"Assessment of coenzyme Q10 tolerability in Huntington\u2019s disease","volume":"11","author":"Feigin","year":"1996","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-180320_ref54","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"issue":"4","key":"10.3233\/JHD-180320_ref55","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/mds.20756","article-title":"CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington\u2019s disease","volume":"21","author":"Dubinsky","year":"2006","journal-title":"Mov Disord"},{"issue":"6","key":"10.3233\/JHD-180320_ref56","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/mds.20018","article-title":"Minocycline in Huntington\u2019s disease: a pilot study","volume":"19","author":"Thomas","year":"2004","journal-title":"Mov Disord"},{"issue":"10","key":"10.3233\/JHD-180320_ref57","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s004150170071","article-title":"Riluzole in Huntington\u2019s disease (HD): an open label study with one year follow up","volume":"248","author":"Seppi","year":"2001","journal-title":"J Neurol"},{"issue":"10","key":"10.3233\/JHD-180320_ref58","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1161\/STROKEAHA.115.010471","article-title":"Fluoxetine maintains a state of heightened responsiveness to motor training early after stroke in a mouse model","volume":"46","author":"Ng","year":"2015","journal-title":"Stroke"},{"key":"10.3233\/JHD-180320_ref59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1745-6215-12-26","article-title":"Sample size requirements for separating out the effects of combination treatments: Randomised controlled trials of combination therapy vs standard treatment compared to factorial designs for patients with tuberculous meningitis","volume":"12","author":"Wolbers","year":"2011","journal-title":"Trials"},{"issue":"10","key":"10.3233\/JHD-180320_ref60","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1212\/WNL.0000000000000187","article-title":"PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease","volume":"82","author":"Rosas","year":"2014","journal-title":"Neurology"},{"issue":"17","key":"10.3233\/JHD-180320_ref61","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/djn267","article-title":"Speeding up the evaluation of new agents in cancer","volume":"100","author":"Parmar","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.3233\/JHD-180320_ref62","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/sim.7159","article-title":"Factorial versus multi?arm multi?stage designs for clinical trials with multiple treatments","volume":"36","author":"Jaki","year":"2017","journal-title":"Stat Med"},{"key":"10.3233\/JHD-180320_ref63","unstructured":"National Institute for Health and Care Excellence (NICE). NICE guideline [NG28] Type 2 diabetes in adults: management. 2015."},{"key":"10.3233\/JHD-180320_ref64","unstructured":"National Institute for Health and Care Excellence (NICE). Clinical guideline [CG127] Hypertension in adults: diagnosis and management. 2011."},{"issue":"9","key":"10.3233\/JHD-180320_ref65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S1474-4422(17)30161-8","article-title":"Identification of genetic variants associated with Huntington\u2019s disease progression: a genome-wide association study","volume":"16","author":"Moss","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.3233\/JHD-180320_ref66","doi-asserted-by":"crossref","unstructured":"Greenland JC , Williams-Gray CH , Barker RA The clinical heterogeneity of Parkinson\u2019s disease and its therapeutic implications. Eur J Neurosci. 2018; doi: 10.1111\/ejn.14094 .","DOI":"10.1111\/ejn.14094"},{"issue":"111","key":"10.3233\/JHD-180320_ref67","doi-asserted-by":"crossref","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","article-title":"Testing the right target and right drug at the right stage","volume":"3","author":"Sperling","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.3233\/JHD-180320_ref68","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/jnnp-2014-307721","article-title":"Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy","volume":"86","author":"Tuohy","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.3233\/JHD-180320_ref69","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-180320_ref70","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1471-4159.2003.01706.x","article-title":"Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington\u2019s disease transgenic mice","volume":"85","author":"Dedeoglu","year":"2003","journal-title":"J Neurochem"},{"issue":"3","key":"10.3233\/JHD-180320_ref71","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington\u2019s disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"issue":"4","key":"10.3233\/JHD-180320_ref72","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mds.10229","article-title":"Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington\u2019s disease","volume":"17","author":"Schiefer","year":"2002","journal-title":"Mov Disord"},{"issue":"2","key":"10.3233\/JHD-180320_ref73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/ana.10614","article-title":"Minocycline and doxycycline are not beneficial in a model of Huntington\u2019s disease","volume":"54","author":"Smith","year":"2003","journal-title":"Ann Neurol"},{"issue":"20","key":"10.3233\/JHD-180320_ref74","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1523\/JNEUROSCI.22-20-08942.2002","article-title":"Therapeutic effects of cystamine in a murine model of Huntington\u2019s disease","volume":"22","author":"Dedeoglu","year":"2002","journal-title":"J Neurosci"},{"issue":"2","key":"10.3233\/JHD-180320_ref75","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nm0202-143","article-title":"Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine","volume":"8","author":"Karpuj","year":"2002","journal-title":"Nat Med"},{"issue":"2","key":"10.3233\/JHD-180320_ref77","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.26101","article-title":"A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington\u2019s disease","volume":"30","author":"Prundean","year":"2015","journal-title":"Mov Disord"},{"issue":"1","key":"10.3233\/JHD-180320_ref78","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1523\/JNEUROSCI.18-01-00156.1998","article-title":"Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington\u2019s disease","volume":"18","author":"Matthews","year":"1998","journal-title":"J Neurosci"},{"issue":"12","key":"10.3233\/JHD-180320_ref79","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J Neurosci"},{"issue":"3","key":"10.3233\/JHD-180320_ref80","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol Dis"},{"issue":"7","key":"10.3233\/JHD-180320_ref81","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1212\/01.WNL.0000090629.40891.4B","article-title":"Creatine supplementation in Huntington\u2019s disease: a placebo-controlled pilot trial","volume":"61","author":"Verbessem","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-180320_ref82","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbadis.2006.03.004","article-title":"Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington\u2019s disease mice","volume":"1762","author":"Smith","year":"2006","journal-title":"Biochim Biophys Acta"},{"issue":"10069","key":"10.3233\/JHD-180320_ref83","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(16)30962-X","article-title":"Stroke","volume":"389","author":"Hankey","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.3233\/JHD-180320_ref84","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington\u2019s disease decades before diagnosis: the Predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10.3233\/JHD-180320_ref85","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1523\/JNEUROSCI.4320-04.2005","article-title":"Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington\u2019s disease mice","volume":"25","author":"Mazarakis","year":"2005","journal-title":"J Neurosci"},{"issue":"5","key":"10.3233\/JHD-180320_ref86","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/hmg\/8.5.839","article-title":"Impaired synaptic plasticity in mice carrying the Huntington\u2019s disease mutation","volume":"8","author":"Usdin","year":"1999","journal-title":"Hum Mol Genet"},{"issue":"10","key":"10.3233\/JHD-180320_ref87","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/hmg\/ddl092","article-title":"Early development of aberrant synaptic plasticity in a mouse model of Huntington\u2019s disease","volume":"15","author":"Milnerwood","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"19","key":"10.3233\/JHD-180320_ref88","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1093\/hmg\/ddl224","article-title":"Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington\u2019s disease","volume":"15","author":"Cummings","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.3233\/JHD-180320_ref89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.tins.2010.08.002","article-title":"Early synaptic pathophysiology in neurodegeneration: insights from Huntington\u2019s disease","volume":"33","author":"Milnerwood","year":"2010","journal-title":"Trends Neurosci"},{"issue":"2","key":"10.3233\/JHD-180320_ref90","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2010.01.008","article-title":"Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington\u2019s disease mice","volume":"65","author":"Milnerwood","year":"2010","journal-title":"Neuron"},{"issue":"12","key":"10.3233\/JHD-180320_ref91","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1038\/nm.2056","article-title":"Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin","volume":"15","author":"Okamoto","year":"2009","journal-title":"Nat Med"},{"issue":"5","key":"10.3233\/JHD-180320_ref92","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1212\/WNL.53.5.1000","article-title":"Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial","volume":"53","author":"Kremer","year":"1999","journal-title":"Neurology"},{"issue":"6","key":"10.3233\/JHD-180320_ref93","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.neuropharm.2007.07.013","article-title":"Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system\u2013too little activation is bad, too much is even worse","volume":"53","author":"Parsons","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.3233\/JHD-180320_ref94","first-page":"7","article-title":"Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease","author":"Arnoux","year":"2018","journal-title":"Elife"},{"issue":"2-3","key":"10.3233\/JHD-180320_ref95","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainresbull.2006.10.028","article-title":"Change in MRI striatal volumes as a biomarker in preclinical Huntington\u2019s disease","volume":"72","author":"Aylward","year":"2007","journal-title":"Brain Res Bull"},{"issue":"7","key":"10.3233\/JHD-180320_ref96","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington\u2019s disease in the TRACK-HD study: analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.3233\/JHD-180320_ref97","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/jnnp.2009.171926","article-title":"Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease","volume":"81","author":"Orth","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.3233\/JHD-180320_ref98","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.biopsych.2008.12.026","article-title":"Abnormal motor cortex excitability in preclinical and very early Huntington\u2019s disease","volume":"65","author":"Schippling","year":"2009","journal-title":"Biol Psychiatry"},{"issue":"Pt 4","key":"10.3233\/JHD-180320_ref99","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/brain\/aws024","article-title":"Altered brain mechanisms of emotion processing in pre-manifest Huntington\u2019s disease","volume":"135","author":"Novak","year":"2012","journal-title":"Brain"},{"issue":"10","key":"10.3233\/JHD-180320_ref100","first-page":"1715","article-title":"fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington\u2019s disease","volume":"25","author":"Paulsen","year":"2004","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.3233\/JHD-180320_ref101","unstructured":"Wild EJ , Tabrizi SJ Huntington\u2019s disease. In: Bates GP , Jones L , Tabrizi SJ , editors. 4th ed. Oxford:Oxford University Press; 2014."},{"issue":"3","key":"10.3233\/JHD-180320_ref102","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cell.2015.07.003","article-title":"Identification of genetic factors that modify clinical onset of Huntington\u2019s disease","volume":"162","author":"Genetic Modifiers of Huntington\u2019s Disease (GeM-HD) Consortium","year":"2015","journal-title":"Cell"},{"issue":"10","key":"10.3233\/JHD-180320_ref103","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1073\/pnas.0308679101","article-title":"Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2019s disease age of onset","volume":"101","author":"Wexler","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.3233\/JHD-180320_ref104","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington\u2019s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.3233\/JHD-180320_ref105","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archneur.63.7.991","article-title":"At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled","volume":"63","author":"Huntington Study Group PHAROS Investigators","year":"2006","journal-title":"Arch Neurol"},{"issue":"10","key":"10.3233\/JHD-180320_ref106","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1038\/ejhg.2016.36","article-title":"22 Years of predictive testing for Huntington\u2019s disease: the experience of the UK Huntington\u2019s Prediction Consortium","volume":"24","author":"Baig","year":"2016","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.3233\/JHD-180320_ref107","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ajmg.b.32016","article-title":"Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease","volume":"159b","author":"Bombard","year":"2012","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"10.3233\/JHD-180320_ref108","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.3233\/JHD-180320_ref109","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.3233\/JHD-180320_ref110","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ , editor Effects of IONIS-HTTRx in patients with early Huntington\u2019s disease, results of the first HTT-lowering drug trial. 70th Annual AAN Meeting; April 21\u201327, 2018 Los Angeles.","DOI":"10.1136\/jnnp-2018-EHDN.261"},{"issue":"12","key":"10.3233\/JHD-180320_ref111","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington\u2019s disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.3233\/JHD-180320_ref112","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1523\/JNEUROSCI.6039-08.2009","article-title":"Decreased BDNF levels are a major contributor to the embryonic phenotype of huntingtin knockdown zebrafish","volume":"29","author":"Diekmann","year":"2009","journal-title":"J Neurosci"},{"issue":"5","key":"10.3233\/JHD-180320_ref113","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1539","article-title":"Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs","volume":"27","author":"Hu","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"47","key":"10.3233\/JHD-180320_ref114","doi-asserted-by":"crossref","first-page":"10166","DOI":"10.1021\/bi101208k","article-title":"Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat","volume":"49","author":"Gagnon","year":"2010","journal-title":"Biochemistry"},{"issue":"23","key":"10.3233\/JHD-180320_ref115","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1093\/hmg\/ddu349","article-title":"Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity","volume":"23","author":"Sun","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"21","key":"10.3233\/JHD-180320_ref116","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.3233\/JHD-180320_ref117","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1089\/hum.2007.116","article-title":"Identification and allele-specific silencing of the mutant huntingtin allele in Huntington\u2019s disease patient-derived fibroblasts","volume":"19","author":"van Bilsen","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"12","key":"10.3233\/JHD-180320_ref118","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/mt.2011.201","article-title":"Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene \/ allele-specific silencing of mutant huntingtin","volume":"19","author":"Carroll","year":"2011","journal-title":"Mol Ther"},{"issue":"1","key":"10.3233\/JHD-180320_ref119","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.drudis.2014.09.011","article-title":"Delivering a disease-modifying treatment for Huntington\u2019s disease","volume":"20","author":"Godinho","year":"2015","journal-title":"Drug Discov Today"},{"issue":"4","key":"10.3233\/JHD-180320_ref120","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/mt.2010.293","article-title":"Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa","volume":"19","author":"Millington-Ward","year":"2011","journal-title":"Mol Ther"},{"issue":"34","key":"10.3233\/JHD-180320_ref121","doi-asserted-by":"crossref","first-page":"14258","DOI":"10.1073\/pnas.1109522108","article-title":"Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins","volume":"108","author":"Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.3233\/JHD-180320_ref122","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1073\/pnas.0501507102","article-title":"RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model","volume":"102","author":"Harper","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.3233\/JHD-180320_ref123","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ymthe.2005.05.006","article-title":"Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6\/1 Huntington\u2019s disease transgenic mice","volume":"12","author":"Rodriguez-Lebron","year":"2005","journal-title":"Mol Ther"},{"issue":"3","key":"10.3233\/JHD-180320_ref124","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","article-title":"Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA","volume":"53","author":"Wang","year":"2005","journal-title":"Neurosci Res"},{"issue":"43","key":"10.3233\/JHD-180320_ref125","doi-asserted-by":"crossref","first-page":"17204","DOI":"10.1073\/pnas.0708285104","article-title":"Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits","volume":"104","author":"DiFiglia","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.3233\/JHD-180320_ref126","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2008.50","article-title":"AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington\u2019s disease","volume":"16","author":"Franich","year":"2008","journal-title":"Mol Ther"},{"issue":"6","key":"10.3233\/JHD-180320_ref127","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/mt.2009.17","article-title":"Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington\u2019s disease mice","volume":"17","author":"Boudreau","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"10.3233\/JHD-180320_ref128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.02.141","article-title":"rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse","volume":"343","author":"Machida","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.3233\/JHD-180320_ref129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/ana.21569","article-title":"Sustained effects of nonallele-specific Huntingtin silencing","volume":"65","author":"Drouet","year":"2009","journal-title":"Ann Neurol"},{"issue":"4","key":"10.3233\/JHD-180320_ref130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1089\/hum.2006.160","article-title":"High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo","volume":"18","author":"Huang","year":"2007","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.3233\/JHD-180320_ref131","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","article-title":"Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease","volume":"101","author":"Yamamoto","year":"2000","journal-title":"Cell"},{"issue":"1","key":"10.3233\/JHD-180320_ref132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(00)80617-0","article-title":"Reversing neurodegeneration: a promise unfolds","volume":"101","author":"Orr","year":"2000","journal-title":"Cell"},{"issue":"4","key":"10.3233\/JHD-180320_ref133","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.3233\/JHD-180320_ref134","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"10.3233\/JHD-180320_ref135","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat Neurosci"},{"issue":"3","key":"10.3233\/JHD-180320_ref136","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jgs.14019","article-title":"Diabetes mellitus as a risk factor for development of depressive symptoms in a population-based cohort of older Mexican americans","volume":"64","author":"Garcia","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"10.3233\/JHD-180320_ref137","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.apmr.2015.08.431","article-title":"Increased lower limb spasticity but not strength or function following a single-dose serotonin reuptake inhibitor in chronic stroke","volume":"96","author":"Gourab","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"10.3233\/JHD-180320_ref138","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jneumeth.2015.09.003","article-title":"So you think you can jump? A novel long jump assessment to detect deficits in stroked mice","volume":"256","author":"Mittal","year":"2015","journal-title":"J Neurosci Methods"},{"issue":"8","key":"10.3233\/JHD-180320_ref139","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2011.70","article-title":"Amyloid-dependent and amyloid-independent stages of Alzheimer disease","volume":"68","author":"Hyman","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.3233\/JHD-180320_ref140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/hmg\/ddp475","article-title":"Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate","volume":"19","author":"Colle","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"1-2","key":"10.3233\/JHD-180320_ref141","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0006-8993(95)01488-8","article-title":"Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector","volume":"713","author":"McCown","year":"1996","journal-title":"Brain Res"},{"issue":"22","key":"10.3233\/JHD-180320_ref142","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/sj.gt.3302087","article-title":"Adeno-associated virus vector-mediated transduction in the cat brain","volume":"10","author":"Vite","year":"2003","journal-title":"Gene Ther"},{"issue":"18","key":"10.3233\/JHD-180320_ref143","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","journal-title":"N Engl J Med"},{"issue":"10036","key":"10.3233\/JHD-180320_ref144","first-page":"3017","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","journal-title":"Lancet"},{"issue":"1","key":"10.3233\/JHD-180320_ref145","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and Mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"Fernandez","year":"2016","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.3233\/JHD-180320_ref146","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/gt.2014.121","article-title":"Efficient central nervous system AAVrh10-mediated intrathecal gene transfer in adult and neonate rats","volume":"22","author":"Hordeaux","year":"2015","journal-title":"Gene Ther"},{"issue":"1-2","key":"10.3233\/JHD-180320_ref147","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2007.04.010","article-title":"The matrix metalloproteinases and CNS plasticity: an overview","volume":"187","author":"Milward","journal-title":"J Neuroimmunol"},{"issue":"6","key":"10.3233\/JHD-180320_ref148","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/mrm.20098","article-title":"Prolonged T*2 values in newborn versus adult brain: Implications for fMRI studies of newborns","volume":"51","author":"Rivkin","year":"2004","journal-title":"Magn Reson Med"},{"key":"10.3233\/JHD-180320_ref149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jtbi.2014.02.025","article-title":"Evolution of acquired resistance to anti-cancer therapy","volume":"355","author":"Foo","year":"2014","journal-title":"J Theor Biol"},{"issue":"10","key":"10.3233\/JHD-180320_ref150","first-page":"923","article-title":"Quantitative model for multiple levels of drug resistance in clinical tumors","volume":"67","author":"Goldie","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"9","key":"10.3233\/JHD-180320_ref151","first-page":"3643","article-title":"The genetic origin of drug resistance in neoplasms: implications for systemic therapy","volume":"44","author":"Goldie","year":"1984","journal-title":"Cancer Res"},{"issue":"3-4","key":"10.3233\/JHD-180320_ref152","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0092-8240(86)90028-5","article-title":"A stochastic model for the origin and treatment of tumors containing drug-resistant cells","volume":"48","author":"Coldman","year":"1986","journal-title":"Bull Math Biol"},{"issue":"25","key":"10.3233\/JHD-180320_ref153","first-page":"1662","article-title":"Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter","volume":"333","author":"Eron","year":"1995","journal-title":"North American HIV Working Party. N Engl J Med"},{"issue":"2","key":"10.3233\/JHD-180320_ref154","doi-asserted-by":"crossref","first-page":"e01586","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of combination therapy for tuberculosis: lessons for future antimicrobial development and application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"issue":"11","key":"10.3233\/JHD-180320_ref155","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"}],"container-title":["Journal of Huntington's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JHD-180320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:50:43Z","timestamp":1777452643000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JHD-180320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,13]]},"references-count":154,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jhd-180320","relation":{},"ISSN":["1879-6397","1879-6400"],"issn-type":[{"value":"1879-6397","type":"print"},{"value":"1879-6400","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,13]]}}}